Evidence map›Paper›PMID 34755060›Full record

ArticleIJU case reports2021

t(6; 11) renal cell carcinoma. A case report successfully diagnosed by using fluorescence in situ hybridization.

Hidekazu Nishizawa, Masaya Baba, Mitsuko Furuya, Ikuma Kato, Ryoma Kurahashi, Yumi Honda, Yoshiki Mikami, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba

Open access · goldAbstract readCase Reports
In one paragraph

Article in IJU case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Hidekazu NishizawaDepartment of Urology Faculty of Life Sciences Kumamoto University Kumamoto City Japan.ORCID https://orcid.org/0000-0001-9315-6650
Masaya BabaLaboratory of Cancer Metabolism International Research Center for Medical Sciences (IRCMS) Kumamoto University Kumamoto Japan.ORCID https://orcid.org/0000-0002-5308-6683
Mitsuko FuruyaPathology Center GeneticLab Co., Ltd Sapporo Japan.ORCID https://orcid.org/0000-0002-6220-8179
Ikuma KatoDepartment of Molecular Pathology Yokohama City University Yokohama Japan.ORCID https://orcid.org/0000-0002-7731-9509
Ryoma KurahashiDepartment of Urology Faculty of Life Sciences Kumamoto University Kumamoto City Japan.ORCID https://orcid.org/0000-0001-6972-8065
Yumi HondaDepartment of Diagnostic Pathology Kumamoto University Hospital Kumamoto Japan.
Yoshiki MikamiDepartment of Diagnostic Pathology Kumamoto University Hospital Kumamoto Japan.
Yoji NagashimaDepartment of Surgical Pathology Tokyo Women's Medical University Hospital Tokyo Japan.
Masatoshi EtoDepartment of Urology Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Tomomi KambaDepartment of Urology Faculty of Life Sciences Kumamoto University Kumamoto City Japan.
Kumamoto University · JPKumamoto University Hospital · JPGenetic Resources Center · JPKyushu University · JPTokyo Women's Medical University Hospital · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDefinitive diagnosis of translocation renal cell carcinoma is challenging. We herein experienced a case of translocation(6;11) renal cell carcinoma, successfully diagnosed by using fluorescence in situ hybridization. CASE PRESENTATION: During the follow-up of a 21-year-old man with Crohn's disease, computed tomography revealed a 40-mm mass in the right kidney. Since imaging could not exclude malignancy, needle biopsy was performed. The histological diagnosis from the biopsy specimen was renal cell carcinoma, but histological typing had not been done adequately. A laparoscopic partial nephrectomy was then performed. Transcription factor EB immunoreactivity was positive, transcription factor EB rearrangement was shown by break apart and fusion fluorescence in situ hybridization. As a result, a definitive diagnosis of t(6; 11) renal cell carcinoma was made. There has been no recurrence for 5 years.

conclusionTranscription factor EB immunohistochemistry and fluorescence in situ hybridization are useful diagnostic tools for renal tumors of young generation.

Indexed as

FISHimmunohistochemistryMiT family translocation renal cell carcinomat(6;11)transcription factor EB (TFEB)

Identifiers

PMID34755060
PMCPMC8560446
OpenAlexW3196132648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.